NCT05809024

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy in High Risk Early HR+/HER2-breast Cancer Based on Molecular Marker

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Yongsheng Wang · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Select the appropriate population for adding CDK4/6 inhibitors therapy in high risk early HR+/HER2-breast cancer based on molecular detection

Conditions

• Locally Advanced Breast Cancer
• Hormone Receptor Positive，HER2-negative Breast Cancer

Interventions

Type	Name	Description
DRUG	letrozole	Hormone receptor positive,HER2 negative participants will receive letrozole as neoadjuvant endocrine therapy，if don't work, CDK4/6 Inhibitor was added.

Timeline

• Start date: 2023-03-01
• Primary completion: 2025-03-25
• Completion: 2026-03-25
• First posted: 2023-04-12
• Last updated: 2023-04-12

Locations

1 site across 1 country: China